Free shipping on all orders over $ 500

A 83-01

Cat. No. M5037
A 83-01 Structure

A83-01; A-83-01

Size Price Availability Quantity
2mg USD 40  USD40 In stock
5mg USD 60  USD60 In stock
10mg USD 100  USD100 In stock
50mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

A-83-01, an inhibitor of TGF-β type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation.The targeting efficacy of single intravenous injections of F-SL combined with A-83-01 was evaluated by measurement of the biodistribution and the antitumor effect in mice bearing murine lung carcinoma M109. A-83-01 temporarily changed the tumor vasculature around 3 h post injection. A-83-01 induced 1.7-fold higher compound accumulation of F-SL in the tumor than liposome alone at 24 h post injection.

*The compound is unstable in solutions, freshly prepared is recommended

Product Citations
Customer Product Validations & Biological Datas
Source Breast Cancer Res Treat (2017). Figure 6. A 83-01
Method MTT assay
Cell Lines SKBR3 cells
Concentrations 1 μM 
Incubation Time 16 h
Results As shown in Fig. 6c that A83-01 alone reduced approximately 17% cell migration of JIMT1 and trastuzumab alone inhibited 20% cell migration, while in combination of A83-01 and trastuzumab synergistically inhibited JIMT1 cell migration up to 90%.
Chemical Information
Molecular Weight 421.52
Formula C25H19N5S
CAS Number 909910-43-6
Solubility (25°C) DMSO 24 mg/mL
Storage -20°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Furutani Y, J Cell Biochem. Role of endogenous TGF-β family in myogenic differentiation of C2C12 cells.

[2] Taniguchi Y, Cancer Sci. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor.

[3] Masayoshi Tojo, et al. Cancer Sci. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta

Related TGF-β Receptor Products
LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist.

LSKL, Inhibitor of Thrombospondin (TSP-1)

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist.


KRFK TFA is a peptide derived from TSP-1, which can activate TGF-β.

Maohuoside A

Maohuoside A potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways


Vicatertide is a TGF beta-1 inhibitor.

Abmole Inhibitor Catalog

Keywords: A 83-01, A83-01; A-83-01 supplier, TGF-β Receptor, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.